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EDITORIAL    
CABANA Trial: The Aftermath after the Negative / 
Neutral Results   
Antonis S. Manolis, MD  
Athens University School of Medicine, Athens, Greece  
Abstract 
The results of the CABANA trial were recently presented at 
the Heart Rhythm Society Meeting in May 2018, indicating that 
ablation in patients with atrial fibrillation (AF) did not confer a 
benefit over drug treatment in the intention-to treat analysis, but 
did so in an on-treatment analysis. The presentation stirred 
commotion in the medical community with fierce controversy 
appearing in the media, mostly related to an apparent willingness 
of electrophysiologists to dispel the first and accept the second 
type of analysis. Rhythmos 2018;13(3): 45-47.   
Key Words: atrial fibrillation; catheter ablation; pulmonary vein 
isolation; antiarrhythmic drug therapy  
Abbreviations: AF = atrial fibrillation; CT = computed tomography; 
CV = cardiovascular; EF = ejection fraction; ICD = implantable 
cardioverter defibrillator; PVI = pulmonary vein isolation; TIA = 
transient ischemic attack   
Introduction  
 The CABANA (Catheter ABlation Versus ANti-
arrhythmic Drug Therapy for Atrial Fibrillation) trial 
(NCT00911508) sponsored by the NIH with additional 
support from industry (including St. Jude Medical, 
Johnson & Johnson, Medtronic, and Boston Scientific) 
was designed to randomize 2200 atrial fibrillation (AF) 
patients to a strategy of catheter ablation versus rate or 
rhythm control drug therapy. 2 Inclusion criteria included 
≥ 1 risk factor for stroke and eligibility for both catheter 
ablation and ≥ 2 anti-arrhythmic or≥ 2 rate control drugs. 
Patients were followed every 3 to 6 months (median 4 
years) and underwent repeat trans-telephonic monitoring, 
Holter monitoring, and CT/MR in a subgroup of patient 
studies to assess the impact of treatment on AF recurrence 
and atrial structure. With 1100 patients in each treatment 
arm, CABANA was projected to have 90% power for 
detecting a 30% relative reduction in the primary 
composite endpoint of total mortality, disabling stroke, 
serious bleeding, or cardiac arrest. Slow enrollment and 
lower than expected event rates prompted a monitoring 
committee and the investigators to expand the primary 
endpoint from overall mortality to a composite of overall 
mortality, disabling stroke, major bleeding, and cardiac 
arrest.   
Results of the CABANA Trial  
The first results of the trial were presented at the Heart 
Rhythm Society Meeting in May 2018 
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(http://abstractsonline.com/pp8/#!/4554/presentation/790
7) (Table 1). The trial finally included 2,204 patients 
(median age 68 years, 63% male, 81% hypertensive, 10% 
with prior stroke or TIA, 4% other thromboembolic events, 
36% class II/III heart failure, 10% cardiomyopathies) 
enrolled at 126 sites from 2009 to 2016, randomized to 
drug therapy (n=1096, 49.7%) and catheter ablation with 
pulmonary vein isolation (PVI) (n=1108) 
(www.acc.org/latest-in-cardiology/clinical-trials/2018/05 
/10/15/57/cabana). Adjunctive ablative procedures were 
used at operator’s discretion. Median ejection fraction (EF) 
was 58%, with 5% with an EF ≤35%. Paroxysmal AF was 
present in 946 (43%) and 1257 (57%) had persistent or 
long-standing persistent AF, all with a median of 1.1 years 
since AF onset prior to enrollment. Median follow-up was 
~4 years. 
In an intention-to-treat analysis, the primary endpoint, 
a composite of clinical events consisting of death, 
disabling stroke, serious bleeding, or cardiac arrest, 
occurred in 89 patients (8%) randomized to ablation and 
101 patients (9.2%) randomized to drugs (hazard ratio-HR 
0.86, p=NS). Also, none of the components of the primary 
endpoint differed significantly.    
Table 1. CABANA Trial Results  
Principal Findings: 
● Intention-to-Treat Analysis → Primary outcome (death, 
disabling stroke, serious bleeding, or cardiac arrest) at 5 years 
for ablation vs drugs: 8% vs 9.2% (hazard ratio -HR 0.86, p=0.3) 
 Death: 5.2% vs 6.1% (ablation vs drugs), p = 0.38 
 Serious stroke: 0.3% vs 0.6%, p = 0.19 
 On Treatment Analysis → Primary endpoint (ablation vs 
drugs): 7.0% vs 10.9%, p = 0.006; all-cause mortality: 4.4% 
vs 7.5%, p = 0.005; death or CV hospitalization: 41.2% vs 
74.9%, p = 0.002  
Secondary outcomes: 
 Death or CV hospitalization: 51.7% vs 58.1% (ablation vs 
drugs), HR 0.83, p = 0.002 
 Time to first AF recurrence: HR 0.53, p < 0.0001 
 Pericardial effusion (PVI): 3%; ablation-related events: 1.8%   
Controversy heightened when Douglas Packer, the 
presenter of the trial, presented the results of the on-
treatment analysis (see discussion below). There was a 
large number of crossovers, and finally 1307 patients 
underwent ablation and 897 received drugs. In this as-
treated analysis, which was prespecified as a sensitivity 
analysis of the primary results, ablation resulted in a 3.9% 
absolute risk reduction in the primary endpoint (p = 0.006) 
and a 3.1% reduction in all-cause death (p = 0.005). In a 
similar per-protocol analysis, ablation reduced the rate of 
the primary endpoint by 27% (HR, 0.73; P= 0.046).  
Adverse events occurred in both groups. About 4% of 
the ablation group had problems related to catheter 
insertion, and 3.4% had complications related to catheter 
manipulation in the heart, including 22 (2.2%) patients 
having pericardial effusion. No atrio-esophageal fistulas 
and no deaths were incurred by the procedure.  
Critique  
Milton Packer, a heart failure specialist and trialist, 
cautioned about the per-protocol and treatment-received 
analyses. "This is an open-label trial, so the only valid way 
of analyzing is intention-to-treat." Without blinded 
randomization, he explains (www.medscape.com/ 
viewarticle/896508?src=wnl_tp10n_180607_mscpedit&u
ac=12462FY&impID=1650872&faf=1#vp_2), 
knowledge of treatment assignment can influence 
adjudication of events. "No one does a per-protocol 
analysis for a drug trial anymore," as they were long ago 
discredited, he said, and the same standard should apply to 
device trials. Before CABANA, "the electrophysiology 
community claimed, or believed, that there was a benefit 
of doing ablation above and beyond making the 
electrocardiogram look better. This trial now provides 
evidence that the claim is not true."  
The headings of some of the media covering the 
announcement of the results of the CABANA trial on 
May 10, 2018 are very characteristic:  
● TCTMD the heart beat: CABANA Misses Primary 
Endpoint, but Electrophysiologists See Support for 
Ablation  
● Forbes: CABANA: No Outcomes Benefit In First Big 
Trial Of AF Ablation   
● Medscape: CABANA: Ablation Disappoints for AF vs 
Drugs, Questions Remain   
● MedPage Today: CABANA Misses Primary But May 
Spur Afib Ablation Anyway   
● Healio: CABANA: Ablation an ‘acceptable treatment 
strategy’ for AF   
● Mass Device:  HRS 2018: Study questions benefit of 
ablation over drug therapy for atrial fibrillation  
 Preliminary subgroup analysis indicated that patients 
younger than 65 years seemed to show a benefit from 
ablation, while patients older than 75 showed little benefit. 
Patients with heart failure seemed to particularly derive 
benefit, which goes along with the results of the CASTLE-
AF trial.2 It should be noted though that subgroup analyses 
are typically underpowered for valid conclusions and thus 
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everybody urges that they should be interpreted with 
caution. 
 Although we’ll have to wait for the formal publication 
of the results of the trial and for more information from the 
subgroup analysis with all its inherent limitations, 
however, this trial was indeed a negative trial, as it did not 
show ablation to be superior to drugs for reducing major 
outcomes. Nevertheless, ablation may be a reasonable 
option for selected patients with AF. It should be noted that 
the trial was a non-blinded trial with all inherent 
limitations of such a trial. Thus, the next rational step may 
lead to a future trial designed to include a sham procedure 
as the placebo-controlled arm in which patients and 
doctors are blinded to ablation. Other recent trials that 
comprised a sham procedure have indicated that is the right 
scientific course of action, like in renal denervation and 
coronary revascularization. However, many 
electrophysiologists seem to oppose this idea as non-
feasible or even unethical (www.tctmd.com/news/cabana-
misses-primary-endpoint-electrophysiologists-see-support-
ablation).   
 Quickly here the results will be refreshed of the other 
randomized controlled trial, CASTLE-AF, which was a 
positive ablation trial, albeit in a very selective patient 
population.2 In CASTLE-AF, a total of 363 patients 
(median age 64 years) with symptomatic paroxysmal or 
persistent AF and NYHA II-IV heart failure (HF) with 
LVEF <35% and an ICD were randomized to catheter 
ablation (n=179) or medical therapy (rate or rhythm 
control) (n=184). Over a median of 37.8 months, the 
primary composite end point (death or HF hospitalization) 
occurred in significantly fewer patients in the ablation 
group than in the medical group (28.5% vs 44.6%, hazard 
ratio-HR 0.62, p=0.007). There were also fewer deaths 
(13.4% vs 25%, HR 0.53, p=0.01), and fewer HF 
hospitalizations (20.7% vs 35.9%; HR 0.56, p=0.004). 
 The trial was criticized by Milton Packer as being a 
small trial in a highly selected patient population with only 
10% of the patients screened for the study finally enrolled. 
(www.medpagetoday.com/blogs/revolutionandrevelation/
71006). The trial was also significantly underpowered to 
test its hypothesis, as it was terminated before reaching its 
prespecified targets, falling short of its planned enrollment 
targets by 32%. Furthermore, randomized patients as well 
as events following randomization were excluded from the 
analysis, which is not the right procedure for an intention-
to-treat analysis. Many patients (n=33) were lost to follow-
up with more patients (n=23) lost to follow-up in the 
intervention group than in the control group. Most 
importantly, the primary analysis was based on just a 
handful of events. Based on all these shortcomings, Packer 
concluded that the trial has serious flaws and it cannot 
provide definitive answers on the utility of ablation in the 
patients who were studied unless these results could be 
replicable in future trials.  
 For both studies, Milton Packer’s common critique was 
that “For most (electrophysiologists), performing catheter 
ablations has become a major source of revenue” in the 
US, directly stating that the reasons of accepting the results 
of the smaller CASTLE-AF trial and denying those of the 
larger CABANA trial were driven by finances (www. 
medpagetoday.com/blogs/revolutionandrevelation/72905).    
Perspective 
 Although ablationists may feel disappointed by the 
CABANA trial results and non-electrophysiologists may 
adopt a reprimanding attitude towards those who 
recommend ablation for reasons of improvement of hard 
endpoints, the truth probably lies somewhere in between. 
A selective and more critical approach to AF ablation 
using participatory medicine in a shared decision model 
between patient/patient’s family and physician might be a 
more reasonable strategy. Improving quality of life via a 
reduction of AF burden and curtailing drug intake, 
achievable via ablation, is important to many symptomatic 
patients but not to all patients, especially to those with 
asymptomatic or silent AF, and may be a futile exercise in 
older patients with a lot of comorbidities. Even in patients 
with heart failure and AF, only a very select group appear 
to benefit the most. 2  
 Thus, for now, let’s wait for the full publication of the 
CABANA trial results and seriously consider the design of 
a future trial with a sham procedure for a more rigorous 
approach to the potent placebo effect that our interventions 
have surprisingly been shown to confer in other instances, 
like with renal denervation for hypertension and coronary 
stenting for stable angina.  
 Until then, let’s concentrate on our individual patient 
and his/her needs, looking for arrhythmia triggers to take 
care (uncontrolled hypertension, alcohol, obesity, sleep 
apnea, stressful situations, extreme exercise, thyroid 
dysfunction, etc), and properly advise our patients about 
their options with drugs and availability of ablation, albeit 
with its potential procedural risks and inherent intricacies, 
so that they can reach an informed and educated decision 
about the desired management of their disease.   
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